Updated September 2026. Statuses checked against FDA and state sources as of September 23, 2026.
Short answer: Is BPC-157 legal for clinics to order and use? Not through any federal compounding pathway yet. BPC-157 is not FDA-approved, is not on FDA's 503A bulks list and is not in FDA's interim "Category 1," so a 503A pharmacy has no federal permission to compound it. FDA took it off the Category 2 safety-risk list in April 2026, and FDA's advisory committee voted in July to recommend it, but FDA has not acted. "Research use only" BPC-157 is not a lawful substitute.
The same is true, with small differences, for TB-500, KPV, MOTs-C and the other peptides in the April 2026 announcement. This guide covers what changed, what didn't, and what to watch for the rest of 2026.
Is BPC-157 legal? How FDA decides what a pharmacy may compound
A 503A pharmacy may compound from a bulk ingredient only if it meets one of three conditions in section 503A of the FD&C Act: the substance has a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on FDA's 503A bulks list. The ingredient must also come from an FDA-registered establishment with a valid certificate of analysis.
BPC-157 meets none of the three. While FDA works through nominations for the bulks list, it sorts nominated substances into interim categories:
- Category 1: FDA generally doesn't object to compounding while it evaluates the substance.
- Category 2: substances FDA has identified as raising significant safety risks.
- Category 3: nominations without enough support to evaluate.
- No category: no interim tolerance at all. This is where BPC-157 sits today.
Category 2 peptides: what the April 2026 removal did and didn't do
On April 15, 2026, FDA announced that 12 peptides would leave Category 2 after seven days because their nominators had withdrawn the nominations. FDA's list shows the change effective April 22, 2026. The 12 were BPC-157, cathelicidin LL-37, dihexa acetate, emideltide (DSIP), epitalon, injectable GHK-Cu, KPV, PEG-MGF, melanotan II, MOTs-C, Semax and TB-500 (FDA Category 2 page; Orrick summary).
What it did not do matters more. Law-firm analyses of the announcement stress that leaving Category 2 does not put a substance on the bulks list or into Category 1. FDA's updated category list (May 14, 2026) places none of these peptides in Category 1 except GHK-Cu for non-injectable routes. FDA's Category 2 page still describes its earlier concern that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration" and raises impurity and characterization questions.
For context, 503A Category 2 now lists only cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10 and quinacrine for intrauterine use (FDA categories list, May 14, 2026).
The July 2026 PCAC votes on BPC-157, TB-500 and other peptides
FDA's Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026 (FDA meeting page). FDA's page posts the meeting materials but did not show the votes when we checked, so the counts below come from a McDermott law-firm summary published July 27, 2026. According to that summary, FDA staff recommended against including each peptide.
| Peptide | Category 2 change | PCAC vote (reported) | Federal status, Sept 23, 2026 |
|---|---|---|---|
| BPC-157 | Removed April 2026 | 8-6 to recommend | Not on bulks list; no category |
| TB-500 | Removed April 2026 | 8-6 to recommend | Not on bulks list; no category |
| KPV | Removed April 2026 | 8-6 to recommend | Not on bulks list; no category |
| MOTs-C | Removed April 2026 | 7-5 to recommend | Not on bulks list; no category |
| Epitalon | Removed April 2026 | 7-4 to recommend | Not on bulks list; no category |
| Semax | Removed April 2026 | 8-5 to recommend | Not on bulks list; no category |
| Emideltide (DSIP) | Removed April 2026 | 6-7, not recommended | Not on bulks list; no category |
| GHK-Cu | Injectable removed April 2026 | Due before end of Feb 2027 | Non-injectable routes in Category 1; injectable in no category |
| LL-37, PEG-MGF, dihexa, melanotan II | Removed April 2026 | Due before end of Feb 2027 | No category |
Two cautions. First, PCAC advises; FDA decides. Second, the committee reviewed each substance for specific nominated uses, and a bulks listing, if it comes, would not be an FDA approval or a finding that the peptide works for anything.
TB-500 legal status
TB-500 (a thymosin beta-4 fragment) tracks BPC-157 exactly: out of Category 2 in April, an 8-6 recommendation in July, and no federal compounding permission today. Growth hormone secretagogues such as CJC-1295, ipamorelin and AOD-9604 are a separate story; see the growth hormone secretagogue page in our regulations tool.
Why research use only peptides can't be used in patients
Vials labeled "research use only" or "not for human consumption" are the most common way BPC-157 reaches clinics. The label doesn't create a legal route to a patient:
- They aren't approved drugs. FDA treats RUO peptides as unapproved new drugs when the seller's marketing shows human use. Its August 24, 2026 warning letter to Royal Peptides, for example, pointed to a "peptide calculator" and bacteriostatic water sold alongside the vials.
- They aren't compounding ingredients. An RUO vial isn't a USP-grade bulk substance from a registered establishment with a certificate of analysis, so it doesn't satisfy section 503A.
- State boards are saying it directly. See Mississippi, below.
Mississippi: a joint board statement on research-grade peptides (August 19, 2026)
Mississippi's Board of Nursing, Board of Pharmacy and State Board of Medical Licensure issued a joint statement on August 19, 2026. It says a provider may not compound, administer or dispense a non-FDA-approved or research-grade peptide to a patient, and that the prohibition includes advising, recommending, supplying and prescribing. It adds that patient consent forms calling a product "research-grade" don't remove a provider's liability, and that providers must buy prescription products and ingredients from entities permitted by the Mississippi Board of Pharmacy.
The wording, "non-FDA approved or research-grade," is broad, and the statement lists no exception for peptides compounded by a licensed pharmacy. Mississippi clinicians should ask the boards how it applies to their situation. We did not find comparable statements from other states in our research, but boards can act quickly; check your state's page in the healing peptides regulations tool.
Peptide compounding 2026: what to watch next
- FDA's decision on the six recommended peptides. McDermott wrote that adding them would require notice-and-comment rulemaking, possibly in 2027 or later, and that interim Category 1 placement or an enforcement-discretion statement is possible.
- The next PCAC meeting, due before the end of February 2027, on GHK-Cu (injectable), dihexa, LL-37, PEG-MGF and melanotan II.
- New nominations. FDA says it does not intend to categorize substances nominated on or after January 7, 2025, so newly nominated peptides won't get Category 1 treatment while they wait.
- Enforcement. FDA's warning-letter database and import alerts, where RUO sellers keep appearing.
What clinics can check before ordering peptides
- Look up the substance's current federal status in MedGrid's peptide regulations tool, which runs live FDA lookups.
- For a 503A prescription, confirm the pharmacy is licensed in the patient's state (see the nonresident pharmacy map), and ask which of the three section 503A conditions its bulk ingredient meets.
- Read how a product is classified, and what 503A, 503B and RUO labels mean, on our regulatory lanes page.
- Keep the pharmacy's answer and the date you checked in your records.
Sources
- FDA, Safety Risks Associated with Certain Bulk Drug Substances for Use in Compounding (Category 2 and withdrawn substances) (2026-04-22)
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1-3) (2026-05-14)
- FDA, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (2026-08-06)
- McDermott (law firm), Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (2026-07-27)
- Orrick (law firm), FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings (2026-04-16)
- Legal Information Institute (U.S. Code), 21 U.S.C. 353a (FD&C Act section 503A), Pharmacy compounding (2026-09-23)
- FDA, Warning Letter: Royal Peptides LLC (MARCS-CMS 734884) (2026-08-24)
- Mississippi Board of Nursing, Board of Pharmacy and State Board of Medical Licensure, Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides (2026-08-19)
Frequently asked questions
Is BPC-157 legal for clinics to use in 2026?
Not through a federal compounding pathway yet. As of September 23, 2026, BPC-157 is not FDA-approved, not on the 503A bulks list and not in FDA's interim Category 1, so a 503A pharmacy has no federal permission to compound it. Its removal from Category 2 in April 2026 and a favorable advisory vote in July did not change that.
Did the FDA approve BPC-157 in 2026?
No. FDA's advisory committee voted 8 to 6 on July 23, 2026 to recommend adding BPC-157 to the 503A bulks list (vote as reported by the law firm McDermott). A bulks-list decision is not a drug approval, and FDA has not yet acted on the vote.
What is the legal status of TB-500?
TB-500 is in the same position as BPC-157: removed from Category 2 in April 2026, recommended by the advisory committee in July 2026 (8 to 6, per McDermott), and not yet on the 503A bulks list or in Category 1.
Can clinics use research use only peptides on patients?
FDA treats 'research use only' peptides marketed for human use as unapproved new drugs, and it sent several warning letters to such sellers in 2026. RUO material also doesn't meet the bulk-ingredient conditions a 503A pharmacy must satisfy. Mississippi's boards said in August 2026 that providers may not administer research-grade peptides to patients.
When could BPC-157 be added to the 503A bulks list?
There is no date. Listing requires FDA to decide and complete notice-and-comment rulemaking; McDermott wrote that this could happen in 2027 or take longer, and that interim Category 1 placement or an enforcement-discretion statement is possible. Check the FDA sources linked in this article before relying on any change.
This article is general information, not legal advice. Peptide rules are changing quickly; confirm current status with FDA, your state boards and your counsel before ordering or prescribing.
Check the rules, then see what verified vendors list. Look up any peptide in the MedGrid regulations tool, and verify your NPI to see what diligence-cleared vendors list for your practice. Sign-up is free.
